Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals

Drug Metabolism Letters

Volumn 3, Issue 3, 2009, Pages 176-180

  Moling, Oswald ^a   Rimenti, Giovanni ^a   Pristerà, Raffaele ^a   Vedovelli, Claudio ^a   Pagani, Leonardo ^a   Spoladore, Greta ^a   Mian, Peter ^a  

^a Ospedale Generale   (Italy)

Author keywords

Amitriptyline; Disulfiram; HIV; Lactic acidosis; Nifedipine; Ritonavir

Indexed keywords

AMITRIPTYLINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; DIDANOSINE; DISULFIRAM; EFAVIRENZ; EMTRICITABINE; GABAPENTIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LORAZEPAM; MAGNESIUM; NIFEDIPINE; PYRIDOXINE; RIBOFLAVIN; RITONAVIR; STAVUDINE; TENOFOVIR; THIAMINE; VIRUS RNA;

ADULT; ALCOHOL ABUSE; ANAMNESIS; ARTICLE; AUTOPSY; BLOOD ANALYSIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE SEVERITY; DRUG POTENTIATION; DRUG RESPONSE; FATALITY; HEPATITIS C; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LIVER CIRRHOSIS; MALE; MULTIPLE ORGAN FAILURE; NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; VIRUS DETECTION;

ACIDOSIS, LACTIC; ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; ANTI-RETROVIRAL AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISULFIRAM; DRUG INTERACTIONS; FATAL OUTCOME; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERTENSION; LIVER; LIVER CIRRHOSIS; MALE; MULTIPLE ORGAN FAILURE; NIFEDIPINE;

HEPATITIS C VIRUS;

EID: 70350714436     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209789352120     Document Type: Article

References (38)

1. Sundar, K.; Suarez, M.; Banogon, P.E.; Shapiro, J.M. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit. Care Med., 1997, 25(8), 1425-1430.
2. Arenas-Pinto, A.; Grant, A.D.; Edwards, S.; Weller, I.V. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex. Transm Infect., 2003, 79(4), 340-343.
3. Ogedegbe, A.E.; Thomas, D.L.; Diehl, A.M. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect. Dis., 2003, 3(6), 329-337. (Pubitemid 36718011)
4. Imhof, A.; Ledergerber, B.; Günthard, H.F.; Haupts, S.; Weber, R. Swiss HIV Cohort Study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin. Infect. Dis., 2005, 41(5), 721-728.
5. Geddes, R.; Knight, S.; Moosa, M.Y.; Reddi, A.; Uebel, K.; Sunpath, H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S. Afr. Med. J., 2006, 96(8), 722-724.
6. Bolhaar, M.G.; Karstaedt, A.S. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin. Infect. Dis., 2007, 45(2), 254-260.
7. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS, 2007, 21(18), 2455-2464.
8. Lewis, W.; Copeland, W.C.; Day, B.J. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab. Invest., 2001, 81(6), 777-790.
9. Anderson, P.L.; Kakuda, T.N.; Lichtenstein, K.A. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis., 2004, 38(5), 743-753.
10. Wei, Y.H.; Lee, H.C. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (Maywood), 2002, 227(9), 671-682.
11. Lee, H.C.; Yin, P.H.; Lu, C.Y.; Chi, C.W.; Wei, Y.H. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem. J., 2000, 348(Pt2), 425-432.
12. DuBose, T.D. Acidosis and alkalosis. In Harrison's Principles of Internal Medicine; Fauci, A.S.; Braunwald, E.; Isselbacher, K.J.; Wilson, J.D.; Martin, J.B.; Kasper, D.L.; Hauser, S.L.; Longo, D.L. 14th ed.; McGraw-Hill Companies: New York, 1998, pp. 277-286.
13. Murphy, M.D.; O'Hearn, M.; Chou, S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis., 2003, 36(8), 1082-1085. (Pubitemid 36513297)
14. Guo, Y.; Fung, H.B. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy, 2004, 24(8), 1089-1094.
15. Rosso, R.; Di Biagio, A.; Ferrazin, A.; Bassetti, M.; Ciravegna, B.W.; Bassetti, D. Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. Pediatr. Infect. Dis. J., 2003, 22(7), 668-670.
16. Rivas, P.; Polo, J.; de Górgolas, M.; Fernández-Guerrero, M.L. Drug points: Fatal lactic acidosis associated with tenofovir. B.M.J., 2003, 327(7415), 711.
17. Worth, L.; Elliott, J.; Anderson, J.; Sasadeusz, J.; Street, A.; Lewin, S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Clin. Infect. Dis., 2003, 37(2), 315-316. (Pubitemid 36930366)
18. Giola, M.; Basilico, C.; Grossi, P. Fatal lactic acidosis associated with tenofovir and abacavir. Int. J. Infect. Dis., 2005, 9(4), 228-229. (Pubitemid 40827165)
19. Birkus, G.; Hitchcock, M.J.; Cihlar, T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother., 2002, 46(3), 716-723. (Pubitemid 34157656)
20. Hansen, A.B.; Mathiesen, S.; Gerstoft, J. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand. J. Infect. Dis., 2004, 36(5), 389-392. (Pubitemid 38967701)
21. Patel, V.; Hedayati, S.S. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. Nat. Clin. Pract. Nephrol., 2006, 2(2), 109-114. (Pubitemid 43355219)
22. Klotz, U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung, 2002, 52(2), 155-161. (Pubitemid 34252579)
23. Ene, M.D.; Roberts, C.J. Pharmacokinetics of nifedipine after oral administration in chronic liver disease. J. Clin. Pharmacol., 1987, 27(12), 1001-1004.
24. Babany, G.; Uzzan, F.; Larrey, D.; Degott, C.; Bourgeois, P.; René, E.; Vissuzaine, C.; Erlinger, S.; Benhamou, J.P. Alcoholic-like liver lesions induced by nifedipine. J. Hepatol., 1989, 9(2), 252-255.
25. Shaw, D.R.; Misan, G.M.; Johnson, R.D. Nifedipine hepatitis. Aust. N. Z. J. Med., 1987, 17(4), 447-448.
26. Abramson, M.; Littlejohn, G.O. Hepatic reactions to nifedipine. Med. J. Aust.,1985, 142(1), 47-48.
27. Rossi, D.R.; Rathbun, R.C.; Slater, L.N. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy, 2002, 22(10), 1312-1316.
28. Baeza, M.T.; Merino, E.; Boix, V.; Climent, E. Nifedipine-lopinavir/ ritonavir severe interaction: a case report. AIDS, 2007, 21(1), 119-120. (Pubitemid 44912552)
29. Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; O'Brien, C.P. The status of disulfiram: a half of a century later. J. Clin. Psychopharmacol., 2006, 26(3), 290-302.
30. Fuller, R.K.; Gordis, E. Does disulfiram have a role in alcoholism treatment today? Addiction, 2004, 99(1), 21-24. (Pubitemid 38142216)
31. Björnsson, E.; Nordlinder, H.; Olsson, R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol., 2006, 44(4), 791-797.
32. Rabkin, J.M.; Corless, C.L.; Orloff, S.L.; Benner, K.G.; Flora, K.D.; Rosen, H.R.; Olyaei, A.J. Liver transplantation for disulfiram-induced hepatic failure. Am. J. Gastroenterol., 1998, 93(5), 830-831.
33. Chick, J. Disulfiram:cautions on liver function; how to supervise. Addiction, 2004, 99(1), 25.
34. Buonopane, A.; Petrakis, I.L. Pharmacotherapy of alcohol use disorders. Subst. Use Misuse, 2005, 40(13-14), 2001-2020.
35. Levy, R.H.; Hachad, H.; Yao, C.; Ragueneau-Majlessi, I. Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database. Curr. Drug Metab., 2003, 4(5), 371-380. (Pubitemid 37279362)
36. Chang, T.K.; Gonzalez, F.J.; Waxman, D.J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 1994, 311(2), 437-442. (Pubitemid 24220166)
37. Balakirev, M.Y.; Zimmer, G. Mitochondrial injury by disulfiram:p two different mechanisms of the mitochondrial permeability transition. Chem. Biol. Interact., 2001, 138(3), 299-311. (Pubitemid 33063642)
38. Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 1981, 30(2), 239-245.